Citi Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)

Citi analyst David Lebowitz reiterated a Neutral rating and $275.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "Next steps: Additional data in Sep with regulatory filing on track for late 2024. Looking ahead, Alnylam plans to share additional data at the Heart Failure Society of America meeting (HFSA; Sep 27-30; Atlanta), with the focus being on additional exploratory analyses. In addition, the company is hosting a TTR investor day on Oct 9, which will focus on the commercial landscape/strategy for vutrisiran in CM. Finally, Alnylam remains on track to submit its sNDA by YE24, which, under a 6- month review period, would set up a potential approval and launch in mid-2025."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $262.69 yesterday.

You May Also Be Interested In

• Londian Wason New Energy Tech opens at $26, above IPO price of $22
• ARAMARK Holdings (ARMK) PT Raised to $70 at Jefferies
• Evercore reports July prescription volumes up 1.9% year-over-year